Eli Lilly and Company vs BioCryst Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Eli Lilly vs BioCryst: A Decade of Gross Profit Trends

__timestampBioCryst Pharmaceuticals, Inc.Eli Lilly and Company
Wednesday, January 1, 20141348600014683100000
Thursday, January 1, 20154636100014921500000
Friday, January 1, 20162365400015567200000
Sunday, January 1, 20172348400016801100000
Monday, January 1, 20182018200016811600000
Tuesday, January 1, 20194473400017598300000
Wednesday, January 1, 20201613600019056500000
Friday, January 1, 202114990600021005600000
Saturday, January 1, 202226423300021911600000
Sunday, January 1, 202332675100027041900000
Monday, January 1, 202436624400001
Loading chart...

Unlocking the unknown

A Tale of Two Companies: Gross Profit Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Eli Lilly and Company and BioCryst Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit over the past decade. Eli Lilly, a stalwart in the industry, has consistently demonstrated robust financial performance, with gross profits soaring by approximately 84% from 2014 to 2023. In contrast, BioCryst Pharmaceuticals, a smaller player, has experienced a remarkable growth spurt, with gross profits increasing by over 2300% during the same period.

This stark difference highlights the dynamic nature of the pharmaceutical sector, where established giants and emerging innovators coexist. Eli Lilly's steady growth underscores its market dominance, while BioCryst's rapid ascent reflects its potential to disrupt the status quo. As we look to the future, these trends offer valuable insights into the evolving landscape of pharmaceutical profitability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025